Elshimy Ghada, Correa Ricardo, Alsayed Mahmoud, Jyothinagaram Sathya
Endocrinology, Diabetes and Metabolism, University of Arizona College of Medicine-Phoenix, Phoenix, USA.
Cureus. 2019 Jul 19;11(7):e5173. doi: 10.7759/cureus.5173.
Fournier's gangrene is an extremely rare infection that can occur in immunocompromised patients, especially those with diabetes. Given the severity of this infection and the new associated link to sodium-glucose cotransporter-2 inhibitors, the US FDA recently issued a warning in August 2018. Few cases of Fournier's gangrene have been reported in the literature in diabetic patients taking these oral medications. We report a case of Fournier's gangrene presenting 10 days after a patient with type 2 diabetes started empagliflozin therapy.
福尼尔坏疽是一种极其罕见的感染，可发生于免疫功能低下的患者，尤其是糖尿病患者。鉴于这种感染的严重性以及与钠-葡萄糖协同转运蛋白2抑制剂的新关联，美国食品药品监督管理局（FDA）于2018年8月发布了一项警告。在服用这些口服药物的糖尿病患者中，文献报道的福尼尔坏疽病例很少。我们报告一例2型糖尿病患者开始恩格列净治疗10天后出现福尼尔坏疽的病例。
